ARTICLE | Clinical News
MEM 3454: Preliminary Phase I data
February 27, 2006 8:00 AM UTC
Preliminary data from the double-blind, placebo-controlled, multi-dose, dose-escalation, Canadian Phase I MAD study in 48 healthy volunteers showed that 15 mg oral MEM 3454 once-daily for 13 days had ...